First Manhattan
NWBO

First Manhattan’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

First Manhattan’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8
Closed – – 1524
2016
Q3 		$0 Hold
8
– – ﹤0.01% 1549
2016
Q2 		$0 Hold
8
– – ﹤0.01% 1598
2016
Q1 		$0 Hold
8
– – ﹤0.01% 1537
2015
Q4 		$0 Hold
8
– – ﹤0.01% 1575
2015
Q3 		$0 Hold
8
– – ﹤0.01% 1558
2015
Q2 		$0 Hold
8
– – ﹤0.01% 1571
2015
Q1 		$0 Hold
8
– – ﹤0.01% 1596
2014
Q4 		$0 Hold
8
– – ﹤0.01% 1612
2014
Q3 		$0 Hold
8
– – ﹤0.01% 1542
2014
Q2 		$0 Hold
8
– – ﹤0.01% 1518
2014
Q1 		$0 Hold
8
– – ﹤0.01% 1531
2013
Q4 		$0 Hold
8
– – ﹤0.01% 1472
2013
Q3 		$0 Hold
8
– – ﹤0.01% 1466
2013
Q2 		$0 Buy
+8
New +$29 ﹤0.01% 1416

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

First Manhattan's NWBO Position: Q4 2016 in Review

First Manhattan sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 8 shares.

First Manhattan first reported a position in NWBO in Q2 2013 and held it in 14 quarters. The position peaked at $0 in Q3 2016. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • First Manhattan reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • First Manhattan sold 8 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016.
  • First Manhattan first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 14 quarters.
  • First Manhattan's Northwest Biotherapeutics, Inc. Common stock position peaked at $0 in Q3 2016.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on First Manhattan's 13F filing for Q4 2016, filed 25 Jan 2017.